Dexamethason for the treatment of exacerbations in multiple sclerosis

niversity Medical Center Groningen (UMCG) (The Netherlands)0 个研究点目标入组 60 人开始时间: 2006年11月22日最近更新: 2021年10月4日

试验速览

暂无简介。

•1. Patients with MS, diagnosed according to the MacDonald criteria with a relapsing-remitting or secondary progressive subtype
•2. Age older than 18 years, male or female
•3. Patients have to be experiencing an exacrebation. Exacerbation is defined as the development of a new symptom or the worsening of an established symptom of MS of a duration of more than 24 hours and in the absence of fever or other disease
•4. The exacerbation must encompass at least one of the following symptoms:
•a. arm or leg paresis
•b. gait problems because of paresis or ataxia
•c. limb ataxia
•d. sensory loss
•e. optic neurtitis
•f. diplopia
•5. The exacerbation is present for no more than seven days at randomisation
•6. Informed consent

•1. Use of corticosteroids in the previous three months
•2. Contraindication for corticosteroid use (psychosis, active peptic ulcer, infection etc.)
•3. Circumstanced in which constant medical monitoring is required (e.g. diabetes mellitus)
•4. Pregnancy and breast-feeding
•5. A MS-relapse in the previous eight weeks

发起方

niversity Medical Center Groningen (UMCG) (The Netherlands)